Highly efficient induced pluripotent stem cell reprogramming of cryopreserved lymphoblastoid cell lines
Keywords:lymphoblastoid cell line, iPSC reprogramming, human, disease modeling, disease genetics
Tissue culture based in-vitro experimental modeling of human inherited disorders provides insight into the cellular and molecular mechanisms involved and the underlying genetic component influencing the disease phenotype. The breakthrough development of induced pluripotent stem cell (iPSC) technology represents a quantum leap in experimental modeling of human diseases, providing investigators with a self-renewing and thus unlimited source of pluripotent cells for targeted differentiation into functionally relevant disease specific tissue/cell types. The existing rich bio-resource of Epstein-Barr virus (EBV) immortalized lymphoblastoid cell line (LCL) repositories generated from a wide array of patients in genetic and epidemiological studies worldwide, many of them with extensive genotypic, genomic and phenotypic data already existing, provides a great opportunity to reprogram iPSCs from any of these LCL donors in the context of their own genetic identity for disease modeling and disease gene identification. However, due to the low reprogramming efficiency and poor success rate of LCL to iPSC reprogramming, these LCL resources remain severely underused for this purpose. Here, we detailed step-by-step instructions to perform our highly efficient LCL-to-iPSC reprogramming protocol using EBNA1/OriP episomal plasmids encoding pluripotency transcription factors (i.e., OCT3/4, SOX2, KLF4, L-MYC, and LIN28), mouse p53DD (p53 carboxy-terminal dominant-negative fragment) and commercially available reprogramming media. We achieved a consistently high reprogramming efficiency and 100% success rate (> 200 reprogrammed iPSC lines) using this protocol.
Handley A, Schauer T, Ladurner AG, Margulies CE. Designing Cell-Type-Specific Genome-wide Experiments. Mol Cell. 2015;58(4):621-31. doi: 10.1016/j.molcel.2015.04.024. PubMed PMID: 26000847.
Kumar S, Blangero J, Curran JE. Induced Pluripotent Stem Cells in Disease Modeling and Gene Identification. Methods Mol Biol. 2018;1706:17-38. doi: 10.1007/978-1-4939-7471-9_2. PubMed PMID: 29423791.
Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154-6. PubMed PMID: 7242681.
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145-7. PubMed PMID: 9804556.
Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76. doi: 10.1016/j.cell.2006.07.024. PubMed PMID: 16904174.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861-72. doi: 10.1016/j.cell.2007.11.019. PubMed PMID: 18035408.
Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917-20. doi: 10.1126/science.1151526. PubMed PMID: 18029452.
Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451(7175):141-6. doi: 10.1038/nature06534. PubMed PMID: 18157115.
Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol. 2008;26(11):1276-84. doi: 10.1038/nbt.1503. PubMed PMID: 18931654.
Kim J, Lengner CJ, Kirak O, Hanna J, Cassady JP, Lodato MA, et al. Reprogramming of postnatal neurons into induced pluripotent stem cells by defined factors. Stem Cells. 2011;29(6):992-1000. doi: 10.1002/stem.641. PubMed PMID: 21563275; PubMed Central PMCID: PMCPMC3409465.
Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, et al. An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells. 2013;31(3):458-66. doi: 10.1002/stem.1293. PubMed PMID: 23193063.
Choi SM, Liu H, Chaudhari P, Kim Y, Cheng L, Feng J, et al. Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood. 2011;118(7):1801-5. doi: 10.1182/blood-2011-03-340620. PubMed PMID: 21628406; PubMed Central PMCID: PMCPMC3158714.
Rajesh D, Dickerson SJ, Yu J, Brown ME, Thomson JA, Seay NJ. Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. Blood. 2011;118(7):1797-800. doi: 10.1182/blood-2011-01-332064. PubMed PMID: 21708888; PubMed Central PMCID: PMCPMC4081297.
Kumar S, Curran JE, Glahn DC, Blangero J. Utility of Lymphoblastoid Cell Lines for Induced Pluripotent Stem Cell Generation. Stem Cells Int. 2016;2016:2349261. doi: 10.1155/2016/2349261. PubMed PMID: 27375745; PubMed Central PMCID: PMCPMC4914736.
Barrett R, Ornelas L, Yeager N, Mandefro B, Sahabian A, Lenaeus L, et al. Reliable generation of induced pluripotent stem cells from human lymphoblastoid cell lines. Stem Cells Transl Med. 2014;3(12):1429-34. doi: 10.5966/sctm.2014-0121. PubMed PMID: 25298370; PubMed Central PMCID: PMCPMC4250214.
Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987;6(9):2743-51. PubMed PMID: 2824192; PubMed Central PMCID: PMCPMC553698.
Kang MS, Kieff E. Epstein-Barr virus latent genes. Exp Mol Med. 2015;47:e131. doi: 10.1038/emm.2014.84. PubMed PMID: 25613728; PubMed Central PMCID: PMCPMC4314583.
Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol. 1990;64(5):2309-18. PubMed PMID: 2157887; PubMed Central PMCID: PMCPMC249392.
Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22(33):5108-21. doi: 10.1038/sj.onc.1206556. PubMed PMID: 12910248.
How to Cite
Authors who publish with JBM agree to the following terms:
- Authors retain copyright and grant JBM right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).